CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects - PubMed (original) (raw)
. 2002 Aug 27;59(4):627-9.
doi: 10.1212/wnl.59.4.627.
S J Teipel, R Zinkowski, K Blennow, H Arai, R Engel, K Hofmann-Kiefer, C McCulloch, U Ptok, R Heun, N Andreasen, J DeBernardis, D Kerkman, H- J Moeller, P Davies, H Hampel
Affiliations
- PMID: 12196665
- DOI: 10.1212/wnl.59.4.627
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects
K Buerger et al. Neurology. 2002.
Erratum in
- Neurology. 2004 Sep 28;63(6):1144
Abstract
In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau(231)) in CSF correlate with progression of cognitive decline. High CSF p-tau(231) levels at baseline, but not total tau protein levels, correlated with cognitive decline and conversion from MCI to AD. Independently, old age and APOE-epsilon 4 carrier status were predictive as well. Our data indicate that an increased p-tau(231) level is a potential risk factor for cognitive decline in patients with MCI.
Similar articles
- Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K. Hampel H, et al. Mol Psychiatry. 2004 Jul;9(7):705-10. doi: 10.1038/sj.mp.4001473. Mol Psychiatry. 2004. PMID: 14699432 - Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P. Maccioni RB, et al. Neurobiol Aging. 2006 Feb;27(2):237-44. doi: 10.1016/j.neurobiolaging.2005.01.011. Epub 2005 Apr 7. Neurobiol Aging. 2006. PMID: 16399209 - Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ. Brys M, et al. Neurobiol Aging. 2009 May;30(5):682-90. doi: 10.1016/j.neurobiolaging.2007.08.010. Epub 2007 Sep 24. Neurobiol Aging. 2009. PMID: 17889968 Free PMC article. - CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.
Mitchell AJ. Mitchell AJ. J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):966-75. doi: 10.1136/jnnp.2008.167791. Epub 2009 May 21. J Neurol Neurosurg Psychiatry. 2009. PMID: 19465413 Review.
Cited by
- Alzheimer Disease.
Apostolova LG. Apostolova LG. Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):419-34. doi: 10.1212/CON.0000000000000307. Continuum (Minneap Minn). 2016. PMID: 27042902 Free PMC article. Review. - Alzheimer's disease in a dish: promises and challenges of human stem cell models.
Young JE, Goldstein LS. Young JE, et al. Hum Mol Genet. 2012 Oct 15;21(R1):R82-9. doi: 10.1093/hmg/dds319. Epub 2012 Aug 2. Hum Mol Genet. 2012. PMID: 22865875 Free PMC article. Review. - Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.
Genius J, Klafki H, Benninghoff J, Esselmann H, Wiltfang J. Genius J, et al. Eur Arch Psychiatry Clin Neurosci. 2012 Nov;262 Suppl 2:S71-7. doi: 10.1007/s00406-012-0362-3. Epub 2012 Sep 18. Eur Arch Psychiatry Clin Neurosci. 2012. PMID: 22986448 Review. - Positive association between plasmatic levels of orexin A and the endocannabinoid-derived 2-arachidonoyl lysophosphatidic acid in Alzheimer's disease.
Forte N, Fernández-Rilo AC, Palomba L, Marfella B, Piscitelli F, De Girolamo P, Di Costanzo A, Di Marzo V, Cristino L. Forte N, et al. Front Aging Neurosci. 2022 Nov 16;14:1004002. doi: 10.3389/fnagi.2022.1004002. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36466600 Free PMC article. - Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
Fagan AM, Perrin RJ. Fagan AM, et al. Biomark Med. 2012 Aug;6(4):455-76. doi: 10.2217/bmm.12.42. Biomark Med. 2012. PMID: 22917147 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous